Introduction to
FFPE Molecularly Annotated Cancer Samples
Molecularly Annotated FFPE Cancer Samples for Precision Research
Molecular annotation adds significant research value to conventional FFPE cancer tissue. Instead of providing only a diagnosis and histological description, molecularly annotated specimens can include information regarding genomic variants, gene fusions, amplifications, protein-expression biomarkers or other molecular characteristics. This enables researchers to select samples according to defined biological features and construct more targeted study cohorts.
Such materials can support precision-oncology research, diagnostic development, pharmaceutical studies and computational pathology. Investigators can examine relationships between molecular alterations and tissue morphology while retaining the ability to perform additional testing on the original FFPE block. Molecular annotation may also reduce the cost associated with broad screening of uncharacterized samples and allow researchers to focus resources on specimens that already meet important study criteria.
Annotated Cancer Tissue for Biomarker and Companion Diagnostic Research
Biomarker and companion diagnostic development requires tumor samples that represent specific molecular and pathological subgroups. Molecularly annotated FFPE cancer samples can help researchers identify cases with relevant mutations, protein-expression levels, gene amplifications or other biomarker characteristics. These specimens may be used to develop and evaluate assays designed to identify patients most likely to benefit from targeted therapies.
Â
Researchers can also construct positive, negative and borderline cohorts to assess analytical performance and biological variability. When clinical information is available, molecular annotations can be combined with treatment exposure or outcome variables to support retrospective exploratory studies. This structured approach allows pharmaceutical and diagnostic developers to work with biologically defined patient populations and accelerate biomarker-focused research.
Molecularly Defined FFPE Cohorts Across Multiple Cancer Types
Cancer research often requires molecularly defined cohorts spanning multiple indications. FFPE samples can be organized according to tumor type and relevant biomarker characteristics across lung, breast, colorectal, ovarian, pancreatic, prostate, renal, melanoma, head and neck and other cancers. Within each indication, researchers may specify mutation status, amplification, fusion status, immunohistochemistry expression or other available molecular criteria.
This enables investigators to compare the biological significance of molecular events across disease contexts. Molecularly defined cohorts are also useful for pan-cancer biomarker research and development of technologies intended to operate across multiple tumor types. Combining standardized pathology review with molecular annotations can improve cohort consistency and help researchers interpret biological differences more accurately.
Annotated FFPE Tumor Samples for AI and Digital Pathology Development
Digital pathology models often require reliable molecular labels to train algorithms that predict biomarkers directly from tissue images. Molecularly annotated FFPE tumor samples provide the ground-truth data needed to investigate relationships between H&E morphology and genomic or protein characteristics. Whole-slide images can be paired with known mutation status, amplification, fusion results or immunohistochemistry measurements to create supervised machine-learning datasets. These materials can also support multimodal models that combine pathology, molecular and clinical information.
By retaining access to the original FFPE tissue, researchers can perform additional validation when computational findings require biological confirmation. Molecularly annotated cancer samples therefore provide an important resource for development of AI-driven precision-oncology technologies.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.